81
5
Cross SA (1994) Pathophysiology of pain. Mayo Clin Proc 69:375–383
Dalton GD, Bass CE, Van Horn CG, Howlett AC (2009) Signal transduction via cannabinoid receptors. CNS
Neurol Disord Drug Targets 8:422–431
Davis RL, Cherry J, Dauwalder B, Han PL, Skoulakis E (1995) The cyclic AMP system and Drosophila learning. Mol Cell Biochem 149–150:271–278
de Lera Ruiz M, Lim YH, Zheng J (2014) Adenosine A2A receptor as a drug discovery target. J Med Chem
57:3623–3650
De Petrocellis L, Nabissi M, Santoni G, Ligresti A (2017) Actions and regulation of ionotropic cannabinoid
receptors. Adv Pharmacol 80:249–289
Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, Bolanowski MA, Bennett CD, Rands E,
Diehl RE, Mumford RA, Slater EE, Sigal IS, Caron MG, Lefkowitz RJ, Strader CD (1986) Cloning of the gene
and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321:75–79
Eiden LE, Weihe E (2011) VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann N Y Acad Sci 1216:86–98
Fergus IV, Connell KL, Ferdinand KC (2015) A comparison of vasodilating and non-VASODILATING betablockers and their effects on cardiometabolic risk. Curr Cardiol Rep 17:38
Ferre S (2010) Role of the central ascending neurotransmitter systems in the psychostimulant effects of
caffeine. J Alzheimer’s Dis: JAD 20(Suppl 1):S35–S49
Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK, Hatcher C, Eltit JM, Ruta
JD, Albizu L, Li Z, Umali A, Shim J, Fabiato A, MacKerell AD Jr, Brezina V, Sealfon SC, Filizola M, GonzalezMaeso J, Logothetis DE (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147:1011–1023
Hoffer A (1967) A program for the treatment of alcoholism: LSD, malvaria and nicotinic acid. In: Abramson
HA (ed) The use of LSD in psychotherapy and alcoholism. Bobbs-Merrill, Indianapolis, pp 343–406
Hokfelt T (2010) Looking at neurotransmitters in the microscope. Prog Neurobiol 90:101–118
Huang ZL, Urade Y, Hayaishi O (2011) The role of adenosine in the regulation of sleep. Curr Top Med Chem
11:1047–1057
Johnson KA, Lovinger DM (2016) Presynaptic G protein-coupled receptors: gatekeepers of addiction?
Front Cell Neurosci 10:264
Kivell BM, Ewald AW, Prisinzano TE (2014) Salvinorin A analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol 69:481–511
Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, Echigo N, Kemmotsu O, Hattori Y,
Gando S (2003) The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release? Anesth Analg 97:1239–1245
Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hubner H, Pardon E, Valant C, Sexton PM, Christopoulos
A, Felder CC, Gmeiner P, Steyaert J, Weis WI, Garcia KC, Wess J, Kobilka BK (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101–106
Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J (2014) Muscarinic acetylcholine
receptors: novel opportunities for drug development. Nat Rev Drug Discov 13:549–560
Landolt HP (2008) Sleep homeostasis: a role for adenosine in humans? Biochem Pharmacol 75:
2070–2079
Lemieux G, Davignon A, Genest J (1956) Depressive states during Rauwolfia therapy for arterial hypertension; a report of 30 cases. Can Med Assoc J 74:522–526
Lewin L (1964) Phantastica, narcotic, and stimulating drugs. their use and abuse. Routledge, London
Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, Khan IA, Feller DR (2007)
Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor
subtypes. J Pharmacol Exp Ther 322:214–221
Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system.
Handb Exp Pharmacol 168:299–325
Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW (2013) Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and
Alzheimer’s disease. Drug Discov Today 18:1185–1199
Merighi A, Salio C, Ferrini F, Lossi L (2011) Neuromodulatory function of neuropeptides in the normal
CNS. J Chem Neuroanat 42:276–287
Mustard JA (2014) The buzz on caffeine in invertebrates: effects on behavior and molecular mechanisms.
Cell Mol Life Sci: CMLS 71:1375–1382
Nehlig A, Armspach JP, Namer IJ (2010) SPECT assessment of brain activation induced by caffeine: no
effect on areas involved in dependence. Dialogues Clin Neurosci 12:255–263
References
5
Cross SA (1994) Pathophysiology of pain. Mayo Clin Proc 69:375–383
Dalton GD, Bass CE, Van Horn CG, Howlett AC (2009) Signal transduction via cannabinoid receptors. CNS
Neurol Disord Drug Targets 8:422–431
Davis RL, Cherry J, Dauwalder B, Han PL, Skoulakis E (1995) The cyclic AMP system and Drosophila learning. Mol Cell Biochem 149–150:271–278
de Lera Ruiz M, Lim YH, Zheng J (2014) Adenosine A2A receptor as a drug discovery target. J Med Chem
57:3623–3650
De Petrocellis L, Nabissi M, Santoni G, Ligresti A (2017) Actions and regulation of ionotropic cannabinoid
receptors. Adv Pharmacol 80:249–289
Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, Bolanowski MA, Bennett CD, Rands E,
Diehl RE, Mumford RA, Slater EE, Sigal IS, Caron MG, Lefkowitz RJ, Strader CD (1986) Cloning of the gene
and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321:75–79
Eiden LE, Weihe E (2011) VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann N Y Acad Sci 1216:86–98
Fergus IV, Connell KL, Ferdinand KC (2015) A comparison of vasodilating and non-VASODILATING betablockers and their effects on cardiometabolic risk. Curr Cardiol Rep 17:38
Ferre S (2010) Role of the central ascending neurotransmitter systems in the psychostimulant effects of
caffeine. J Alzheimer’s Dis: JAD 20(Suppl 1):S35–S49
Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK, Hatcher C, Eltit JM, Ruta
JD, Albizu L, Li Z, Umali A, Shim J, Fabiato A, MacKerell AD Jr, Brezina V, Sealfon SC, Filizola M, GonzalezMaeso J, Logothetis DE (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147:1011–1023
Hoffer A (1967) A program for the treatment of alcoholism: LSD, malvaria and nicotinic acid. In: Abramson
HA (ed) The use of LSD in psychotherapy and alcoholism. Bobbs-Merrill, Indianapolis, pp 343–406
Hokfelt T (2010) Looking at neurotransmitters in the microscope. Prog Neurobiol 90:101–118
Huang ZL, Urade Y, Hayaishi O (2011) The role of adenosine in the regulation of sleep. Curr Top Med Chem
11:1047–1057
Johnson KA, Lovinger DM (2016) Presynaptic G protein-coupled receptors: gatekeepers of addiction?
Front Cell Neurosci 10:264
Kivell BM, Ewald AW, Prisinzano TE (2014) Salvinorin A analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol 69:481–511
Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, Echigo N, Kemmotsu O, Hattori Y,
Gando S (2003) The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release? Anesth Analg 97:1239–1245
Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hubner H, Pardon E, Valant C, Sexton PM, Christopoulos
A, Felder CC, Gmeiner P, Steyaert J, Weis WI, Garcia KC, Wess J, Kobilka BK (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101–106
Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J (2014) Muscarinic acetylcholine
receptors: novel opportunities for drug development. Nat Rev Drug Discov 13:549–560
Landolt HP (2008) Sleep homeostasis: a role for adenosine in humans? Biochem Pharmacol 75:
2070–2079
Lemieux G, Davignon A, Genest J (1956) Depressive states during Rauwolfia therapy for arterial hypertension; a report of 30 cases. Can Med Assoc J 74:522–526
Lewin L (1964) Phantastica, narcotic, and stimulating drugs. their use and abuse. Routledge, London
Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, Khan IA, Feller DR (2007)
Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor
subtypes. J Pharmacol Exp Ther 322:214–221
Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system.
Handb Exp Pharmacol 168:299–325
Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW (2013) Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and
Alzheimer’s disease. Drug Discov Today 18:1185–1199
Merighi A, Salio C, Ferrini F, Lossi L (2011) Neuromodulatory function of neuropeptides in the normal
CNS. J Chem Neuroanat 42:276–287
Mustard JA (2014) The buzz on caffeine in invertebrates: effects on behavior and molecular mechanisms.
Cell Mol Life Sci: CMLS 71:1375–1382
Nehlig A, Armspach JP, Namer IJ (2010) SPECT assessment of brain activation induced by caffeine: no
effect on areas involved in dependence. Dialogues Clin Neurosci 12:255–263
References